"Efficacy Of 1.2% Rosuvastatin Gel In The Management Of Infrabony Defects"

Dr. D. Y. Patil Dental College & Hospital10 enrolled

Overview

Study aims to evaluate clinical and radiographic effectiveness of 1.2% Rosuvastatin gel in the treatment of Infrabony defects in chronic periodontitis patients.

Source from where the patients will be selected: 10 patients with chronic periodontitis having two or more infrabony defects will be selected from the Outpatient section of Dept. of Periodontology, Dr. D. Y. Patil Dental College and Hospital, Pimpri, Pune - 18. A detailed clinical examination, case history and written consent will be obtained from all the participants. Before surgery, each patient will be given careful instructions regarding proper oral hygiene measures. A full-mouth phase I therapy will be performed. A periodontal re-evaluation will be performed after 4 to 6 weeks of phase 1 therapy to confirm the desired sites for the study. The selected sites will be divided randomly by using a Sequentially numbered, opaque, sealed envelopes (SNOSE) randomization into control and test sites. The control site will be treated with Access Flap Surgery (AFS), whereas test sites will be treated with AFS and 1.2% Rosuvastatin gel. Suitable antibiotics and analgesics will be prescribed along with Chlorhexidine digluconate rinses (0.2%) twice daily for 14 days. Patients will be examined at 4 weeks, 3 and 6 month after surgery.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Adult Periodontitis

Interventions

RosuvastatinDRUG

Test sites were treated with access flap surgery and 1.2% Rosuvastatin gel

Eligibility

Sex: ALLMin age: 30 YearsMax age: 50 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Age group between 30-50 years * Probing pocket depth ≥ 5mm following initial therapy. * Suitable interproximal angular infrabony defects of ≥3mm. * Involved teeth should be vital and asymptomatic. * Systemically healthy patients. * Patients who demonstrate acceptable oral hygiene prior to access flap surgery. * Patients agreed to sign informed consent and willing to return for the follow up visits. Exclusion Criteria: * Systemic statin therapy * Known or suspected allergy to the statin group * Allergy to sulfur containing drugs * History of aggressive periodontitis. * Presence of gingival recession at the surgical site. * Mobility of study teeth ≥ grade I. * Use of tobacco in any form. * Pregnant and lactating women. * patients who have received any anti-inflammatory drugs and antibiotics in the previous six months. * H/O osteoporosis.

Locations (1)

Sukhada Deo

Pune, Maharashtra, India

Outcomes

Primary Outcomes

Bone fill

Radiographic parameter measuring distance from cemento-enamel junction to the base of the defect. Difference in the measurement at the end of 6 months shows the amount of bone fill

Time frame: 6 months

Secondary Outcomes

Probing depth

Clinical parameters- Reduction in this parameter is desired at the end of 6 months

Time frame: 6 months

relative attachment level

Clinical parameters- Reduction in this parameter at the end of 6 months shows gain in attachment

Time frame: 6 months

plaque index

Clinical parameters- Reduction in plaque index at the end of 6 months shows improvement in gingival health

Time frame: 6 months

bleeding index

Clinical parameters- Reduction in bleeding index at the end of 6 months shows improvement in gingival health

Time frame: 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.